COLORADO SPRINGS, Colo., June 7 /PRNewswire-FirstCall/ -- Spectranetics Corporation announced today it has appointed Donald Fletcher as Vice President of Quality Assurance and Regulatory Compliance. Mr. Fletcher replaces Adrian Elfe, who will be retiring following a transition period.
Mr. Fletcher has more than 30 years experience managing quality assurance and operations functions in the medical device and pharmaceutical industries. He was previously Director of Quality Assurance at Medtronic Vascular Products, with responsibilities at the division's four manufacturing sites. Prior to that, he was Director of Manufacturing Operations and Quality Systems at QTL Biosystems, and Vice President of Operations for Sigma Diagnostics. Mr. Fletcher holds a Bachelor Degree in Biological Sciences from California State University, San Jose.
"Don Fletcher brings extensive experience in manufacturing and operations, including overseeing the quality of highly regulated Class III products for one of the world's leading medical device companies," said John G. Schulte, Spectranetics' President and Chief Executive Officer. "His expertise will play an important role as we continue to expand our operations and develop new products."
"On behalf of the entire Company, I also want to thank Adrian Elfe for the contributions he has made to our growth and success during 17 years of outstanding service to Spectranetics," said Schulte.
About Spectranetics
Founded in 1984, Spectranetics manufactures and sells the only excimer laser approved in the United States, Europe and Japan for use in minimally invasive cardiovascular procedures. This technology treats complex cardiovascular conditions by photo-ablating multiple lesion types into tiny particles that are easily absorbed into the blood stream. The Company's disposable catheters use high-energy "cool" ultraviolet light to vaporize arterial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit www.spectranetics.com.
Safe Harbor Statement
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, unexpected delays or costs associated with the Company's relocation and consolidation of its headquarters and manufacturing operations, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.
COMPANY CONTACT: Spectranetics Corporation Guy Childs, Chief Financial Officer (719) 633-8333 INVESTOR & MEDIA CONTACTS: Lippert/Heilshorn & Associates, Inc. Bruce VossDon Markley (310) 691-7100
Spectranetics CorporationCONTACT: Guy Childs, Chief Financial Officer of Spectranetics Corporation,+1-719-633-8333; or Investor & Media Contacts, Bruce Voss or Don Markley,both of Lippert\Heilshorn & Associates, Inc., +1-310-691-7100, forSpectranetics Corporation
Web site: http://www.spectranetics.com/
